Time of Hematopoietic Reconstruction
Conditions
Brief summary
Increasing experience of Ruxolitinib pre-allo SCT and data concerning Ruxolitinib during transplantation 1. Diagnosis MF(includ Post-ET,Post-PV,PMF,MDS/MPN with MF) 2. With at least two month Ruxolitinib treatment prior to transplantation 3. DAC+BF as myeloablative conditioning regimen 4. CSA from day -3 and MMF from day +1 until day 28 ATG Neovii® at dose of 7.5mg/KG for mismatch donor 5. received Rux at +6d in ASCT and continued to +60d
Interventions
OTHERcomprehensive treatment regimen
1. Diagnosis MF(includ Post-ET,Post-PV,PMF，MDS/MPN with MF) 2. With at least two month Ruxolitinib treatment prior to transplantation 3. DAC+BF as myeloablative conditioning regimen 4. received Rux at +5d in ASCT and continued to +60d
Sponsors
xuna
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
1. Age 18-60 years old, gender is not limited; 2. Diagnosis MF(includ Post-ET,Post-PV,PMF) according to 2016 WHO 3. With at least two month Ruxolitinib treatment before transplantation 4. Informed consent of the patient or his legal representative
Exclusion criteria
1. HCT-CI score≥2 2. Woman who is pregnant or nursing 3. MPN Patients who have received allogeneic hematopoietic stem cell transplantation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Time of neutrophils reconstruction | 1 year | Neutrophils count≧0.5G/L without G-CSF |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The incidence rate of GVHD | 1 year | The incidence rate of aGVHD and cGVHD |
Countries
China
Contacts
Primary Contactna J xu
Outcome results
None listed